Also trades as: AQS.V (TSXV) · $vol 0M
AQSZF OTC
Aequus Pharmaceuticals Inc.
1W: +0.0%
1M: +0.0%
3M: -73.1%
YTD: -41.7%
1Y: -66.7%
3Y: -96.5%
5Y: -99.4%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$584K
+129.2% ▲
5Y CAGR: -18.6%
Gross Profit
$332K
+131.3% ▲
5Y CAGR: -27.3%
Operating Income
-$2M
+24.6% ▲
Net Income
-$2M
+26.5% ▲
EPS (Diluted)
$-0.02
+26.8% ▲
EBITDA
-$2M
+33.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $3M | $3M | $1M | $255K | $584K |
| YoY Growth | +58.8% | +4.7% | -49.2% | -81.5% | +129.2% |
| Cost of Revenue | $0 | $43K | $233K | $111K | $252K |
| Gross Profit | $3M | $3M | $1M | $144K | $332K |
| Gross Margin | 100.0% | 98.4% | 83.1% | 56.4% | 56.9% |
| R&D Expenses | $55K | $297K | $169K | $301K | $0 |
| SG&A Expenses | $3M | $4M | $3M | $3M | $2M |
| Operating Expenses | $3M | $4M | $4M | $3M | $2M |
| Operating Income | -$780K | -$2M | -$3M | -$3M | -$2M |
| Operating Margin | -30.1% | -59.2% | -187.2% | -1106.4% | -364.1% |
| Interest Expense | $520K | $455K | $214K | $145K | $253K |
| Income Before Tax | -$1M | -$2M | -$3M | -$3M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1M | -$2M | -$3M | -$3M | -$2M |
| Net Margin | -40.3% | -66.7% | -232.7% | -1163.1% | -372.7% |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 |
| EBITDA | -$315K | -$1M | -$3M | -$3M | -$2M |
| Shares Outstanding | 93M | 129M | 133M | 133M | 133M |